{"id":"abt-126","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01095562","NCT01655680","NCT01527916","NCT01678755","NCT01834638","NCT00948909","NCT01549834","NCT00959634","NCT01043458","NCT00867399","NCT01676935","NCT00912431","NCT01690195","NCT01482845"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2009","type":"neutral","milestone":"Phase 1 Initiated","description":"A Safety and Tolerability Study of ABT-126 in Elderly — Alzheimer's Disease"},{"date":"2010","type":"neutral","milestone":"Phase 2 Initiated","description":"Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease — Alzheimer's Disease"}],"aiSummary":"ABT-126 is a new treatment being evaluated for Mild to Moderate Alzheimer's Disease. Clinical trials are currently underway to assess its efficacy and safety. These trials also examine its pharmacokinetic properties and impact on biomarkers.","brandName":"ABT-126","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"The provided text does not contain information about the mechanism of action of ABT-126. Therefore, a plain English explanation cannot be generated from the source data.","oneSentence":"ABT-126 is being studied as a potential treatment for mild to moderate Alzheimer's disease in clinical trials.","technicalDetail":"The provided text does not contain information about the technical details of ABT-126’s mechanism. Therefore, a precise scientific mechanism cannot be generated from the source data."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ABT-126","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01095562","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":207,"indication":"Cognitive Deficits in Schizophrenia","completionDate":"2011-09"},{"nctId":"NCT01655680","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsm","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":432,"indication":"Schizophrenia","completionDate":"2014-07"},{"nctId":"NCT01527916","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":438,"indication":"Alzheimer's Disease","completionDate":"2013-11"},{"nctId":"NCT01678755","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":157,"indication":"Schizophrenia","completionDate":"2014-03"},{"nctId":"NCT01834638","phase":"Phase 2","title":"Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855","status":"TERMINATED","sponsor":"AbbVie","isPivotal":false,"enrollment":268,"indication":"Schizophrenia","completionDate":"2014-11"},{"nctId":"NCT00948909","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":274,"indication":"Alzheimer's Disease","completionDate":"2010-11"},{"nctId":"NCT01549834","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibi","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":434,"indication":"Alzheimer's Disease","completionDate":"2013-10"},{"nctId":"NCT00959634","phase":"Phase 1","title":"","status":"COMPLETED","sponsor":"Abbott","isPivotal":false,"enrollment":20,"indication":"Healthy Volunteers","completionDate":""},{"nctId":"NCT01043458","phase":"Phase 1","title":"A Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ABT-126 in Stable Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Abbott","isPivotal":false,"enrollment":16,"indication":"Schizophrenia","completionDate":""},{"nctId":"NCT00867399","phase":"Phase 1","title":"A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects","status":"COMPLETED","sponsor":"Abbott","isPivotal":false,"enrollment":30,"indication":"Alzheimer's Disease","completionDate":""},{"nctId":"NCT01676935","phase":"Phase 2","title":"Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985","status":"TERMINATED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":349,"indication":"Alzheimer's Disease","completionDate":"2014-03"},{"nctId":"NCT00912431","phase":"Phase 1","title":"A Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in the Cerebrospinal Fluid (CSF) of Healthy Subjects","status":"COMPLETED","sponsor":"Abbott","isPivotal":false,"enrollment":10,"indication":"Healthy","completionDate":""},{"nctId":"NCT01690195","phase":"Phase 2","title":"Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completi","status":"TERMINATED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":false,"enrollment":343,"indication":"Alzheimer's Disease","completionDate":"2014-02"},{"nctId":"NCT01482845","phase":"Phase 1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","status":"COMPLETED","sponsor":"Abbott","isPivotal":false,"enrollment":20,"indication":"Alzheimer's Disease","completionDate":"2012-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}